


Amendments to the Claims:

This listing of claims as required by 37 C.F.R. 1.121 will replace all prior versions and listing of claims in the application.

1-8. (Cancelled)

9. (Original) An immunostimulatory oligonucleotide compound comprising an immunostimulatory domain of formula (II):



wherein

Y is cytidine, 2'-deoxycytidine, or a non-natural pyrimidine nucleoside;

Z is guanosine, 2'-deoxyguanosine, or a non-natural purine nucleoside;

X1 is a naturally occurring nucleoside or an immunostimulatory moiety selected from the group consisting of C3-alkyl linker, 2-aminobutyl-1,3-propanediol linker, and β -L-deoxynucleoside;


X2 is a naturally occurring nucleoside or an immunostimulatory moiety that is an amino linker;

X3 is a naturally occurring nucleoside an immunostimulatory moiety that is a nucleoside methylphosphonate;

X4 is a naturally occurring nucleoside an immunostimulatory moiety selected from the group consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside;

provided that at least one of X1, X2, X3, and X4 is an immunostimulatory moiety.

10. (Original) The immunostimulatory oligonucleotide compound of claim 9, wherein Y is a non-natural pyrimidine nucleoside.
11. (Original) The immunostimulatory oligonucleotide compound of claim 10, wherein Y has the formula (I):



(I)

wherein D is a hydrogen bond donor, D' is selected from the group consisting of hydrogen, hydrogen bond donor, hydrogen bond acceptor, hydrophilic group, hydrophobic group, electron withdrawing group and electron donating group, A is a hydrogen bond acceptor or a hydrophilic group, X is carbon or nitrogen, and S is a pentose or hexose sugar ring, provided that Y is not cytidine or deoxycytidine.

12-38. (Cancelled)